
QRxPharma Ltd - Strategic SWOT Analysis Review
Description
QRxPharma Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
QRxPharma Ltd (QRxPharma) develops and commercializes treatments for pain management and abuse prevention products. The company’s product portfolio includes late and early-stage clinical drug candidates. QRxPharma’s dual opioid product portfolio includes Moxduo IR (Q8003), an immediate-release oral capsule for the treatment of acute management of moderate to severe pain; Moxduo IV (Q8012), an intravenous formulation for moderate to severe hospital-based pain; and Moxduo CR (Q8011), a controlled release oral tablet being developed is in clinical trial for treatment of chronic pain. The company’s abuse-deterrent technology called Stealth Beadlets has been developed for controlled release Moxduo formulation. It has operations in the US and Australia. QRxPharma is headquartered in Sydney, New South Wales, Australia.
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
QRxPharma Ltd (QRxPharma) develops and commercializes treatments for pain management and abuse prevention products. The company’s product portfolio includes late and early-stage clinical drug candidates. QRxPharma’s dual opioid product portfolio includes Moxduo IR (Q8003), an immediate-release oral capsule for the treatment of acute management of moderate to severe pain; Moxduo IV (Q8012), an intravenous formulation for moderate to severe hospital-based pain; and Moxduo CR (Q8011), a controlled release oral tablet being developed is in clinical trial for treatment of chronic pain. The company’s abuse-deterrent technology called Stealth Beadlets has been developed for controlled release Moxduo formulation. It has operations in the US and Australia. QRxPharma is headquartered in Sydney, New South Wales, Australia.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
19 Pages
- Section 1 - About the Company
- QRxPharma Ltd - Key Facts
- QRxPharma Ltd - Key Employees
- QRxPharma Ltd - Major Products and Services
- QRxPharma Ltd - History
- QRxPharma Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Section 2 – Company Analysis
- Company Overview
- QRxPharma Ltd - Business Description
- QRxPharma Ltd - Corporate Strategy
- QRxPharma Ltd - SWOT Analysis
- SWOT Analysis - Overview
- QRxPharma Ltd - Strengths
- QRxPharma Ltd - Weaknesses
- QRxPharma Ltd - Opportunities
- QRxPharma Ltd - Threats
- QRxPharma Ltd - Key Competitors
- Section 3 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- QRxPharma Ltd, Key Facts
- QRxPharma Ltd, Key Employees
- QRxPharma Ltd, Major Products and Services
- QRxPharma Ltd, History
- QRxPharma Ltd, Subsidiaries
- QRxPharma Ltd, Joint Venture
- QRxPharma Ltd, Key Competitors
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.